TOLREMO therapeutics’ Post

Just In: The Breast Cancer Drug Market In 2023, sales of leading breast cancer drugs reached approximately $28 billion. The primary agents driving this growth were CDK4/6 inhibitors and HER2-targeted therapies. For a deeper dive into emerging treatments & market trends, explore this latest analysis 👉 https://lnkd.in/dU-sKFqe @NatRevDrugDisc #bcsm #trendings

Onchilles Pharma, a San Diego-based biotech company, presented promising preclinical data at the AACR annual meeting, showing a new molecule to be effective in treating all cancer types. Unlike other cancer treatments that target specific mutations, this molecule has variability and a nonspecific mechanism of action, making it unique. They plan to begin Phase 1 clinical trials later this year, after successfully testing the molecule on 60 different cancer types spanning 13 different anatomical locations. The first study is expected to show reductions in tumor size. For more on Onchilles' ground-breaking research, subscribe to SDBJ.com. https://lnkd.in/gR-rCQzE

Antibody drug conjugates (ADC) could become the future of targeted therapy, according to Dr. Toshimitsu Uenaka, President of Eisai’s Epochal Precision Anti-Cancer Therapeutics (EPAT) Discovery Center. Check out the article he authored for Onco'Zine - The International Oncology Network to learn more about the potential role of ADCs in #cancer care. Link to the article: https://lnkd.in/gBVFAZGe

Anticancer activity of Hedyotis corymbosa nanoliposomes targeting estrogen receptor-alpha in breast cancer cells: In silico and in vitro studies. https://ow.ly/P8TJ50Qx2jA #Cancer #HerbalMedicine #MedicinalPlants #Pharmacology #Pharmacy

In this study, our collaborators at Grey Wolf Therapeutics have shown that inhibition of ERAP2 modulates the presented HLA class I #immunopeptidome. 🎉 Grey Wolf leveraged our #TrueDiscovery® Immunopeptidome Profiling services to identify an increase in 9-mers and a reduction in 8-mers HLA I peptides upon inhibition of ERAP2. 🚀 Download the poster. https://lnkd.in/dZuaifND #Oncology #Proteomics #MassSpectrometry✨

In addition to being asked, “Why CD24?” – I also get asked, “How is your lead drug candidate, PHST001, differentiated?” Due to the complex glycosylation patterns on CD24, not all antibodies against this target are created equal. We have engineered PHST001 to interact with all glyco-variants of CD24, which enables potent activity. And our preclinical data show that we are on the right track. Macrophage checkpoint inhibitors hold tremendous promise, and I believe that PHS001 can strike the right balance of safety and efficacy that is crucial to success. Thanks @PharmaShots for the opportunity to discuss the potential impact of PHST001, how it works, and the impact it could make on the field of cancer immunotherapy.

📰 #NSCLC | ASCO24: J&J's subQ Rybrevant matches efficacy, shrinks infusion time in Phase III trial "The PALOMA-3 trial, presented Friday at the American Society of Clinical Oncology (ASCO) annual meeting, is testing the SC formulation of J&J's EGFR/MET-targeting bispecific antibody in 418 patients with EGFR-mutated, advanced or metastatic non-small-cell lung cancer (NSCLC) and exon 19 deletion or L858R mutations [...]" https://hubs.ly/Q02zY4Bq0 FirstWord Pharma

"Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic agents to precisely target and eliminate cancer cells." In our latest blog, Translational Drug Development (TD2) shares several key trends that are shaping the future of ADC development. Read it now: https://lnkd.in/gQ7pr2hQ

Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight: The dynamics of the metastatic prostate cancer market are anticipated to change in the coming years owing to the rise in the number of companies taking interest in the development of specific drugs for mCRPC and nmCRPC along with increasing awareness and penetration of already approved...

Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/TvgwF4 showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/chsXvR 🤝